A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose-ranging, Parallel Group Study To Evaluate Safety And Efficacy Of Pf-04937319 And Glimepiride In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Phase of Trial: Phase II
Latest Information Update: 03 Feb 2017
At a glance
- Drugs PF 4937319 (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Pfizer
- 07 Jun 2017 Biomarkers information updated
- 03 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Feb 2013 Planned End Date changed from 1 Jan 2013 to 1 Feb 2013 as reported by ClinicalTrials.gov.